Healthcare -
Biotechnology - NASDAQ - US
$ 0.46
-1.7 %
$ 65.1 M
Market Cap
-1.92
P/E
1. INTRINSIC VALUE
Balance Sheet
Applied Therapeutics, Inc.
| Current Assets | 83.6 M |
| Cash & Short-Term Investments | 79.4 M |
| Receivables | 0 |
| Other Current Assets | 4.25 M |
| Non-Current Assets | 3.04 M |
| Long-Term Investments | 0 |
| PP&E | 2.79 M |
| Other Non-Current Assets | 253 K |
| Current Liabilities | 27.3 M |
| Accounts Payable | 4.43 M |
| Short-Term Debt | 812 K |
| Other Current Liabilities | 22.1 M |
| Non-Current Liabilities | 2.39 M |
| Long-Term Debt | 4.78 M |
| Other Non-Current Liabilities | -2.39 M |
EFFICIENCY
Earnings Waterfall
Applied Therapeutics, Inc.
| Revenue | 455 K |
| Cost Of Revenue | 425 K |
| Gross Profit | 30 K |
| Operating Expenses | 105 M |
| Operating Income | -104 M |
| Other Expenses | 1.32 M |
| Net Income | -106 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Applied Therapeutics, Inc.
| Net Income | -106 M |
| Depreciation & Amortization | 425 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 13.5 M |
| Change in Working Capital | 2.52 M |
| Others | 4.74 M |
| Free Cash Flow | -84.3 M |
Wall Street Analysts Price Targets
Applied Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for APLT of $4.5 , with forecasts ranging from
a
low of
$4 to a high of $5 .
APLT Lowest Price Target
Wall Street Target
4 USD
769.57%
APLT Average Price Target
Wall Street Target
4.5 USD
878.26%
APLT Highest Price Target
Wall Street Target
5 USD
986.96%
4. DIVIDEND
ANALYSIS
APLT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Applied Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
94.8 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
4.92 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Applied Therapeutics Announces Key Leadership Appointments
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.
globenewswire.com
- 1 month ago
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat.Reflective of the peripheral neuropathy experienced by patients with CMT-SORD. Govorestat remains generally safe and well tolerated Company remains committed to potential NDA submission of govorestat for treatment of CMT-SORD in 2025 NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare disease, today presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease, in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland.
globenewswire.com
- 2 months ago
Applied Therapeutics Reports First Quarter 2025 Financial Results
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting
globenewswire.com
- 2 months ago
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
globenewswire.com
- 2 months ago
NET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
globenewswire.com
- 3 months ago
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company's Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
globenewswire.com
- 3 months ago
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions
globenewswire.com
- 4 months ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130443&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 5 months ago
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130340&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 5 months ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc.(APLT) Shareholders
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130271&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 5 months ago
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130235&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 5 months ago
APLT DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ:APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
accessnewswire.com
- 5 months ago
8. Profile
Summary
Applied Therapeutics, Inc. APLT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 65.1 M
Dividend Yield
0.00%
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Contact
545 Fifth Avenue, New York City, NY, 10017
https://www.appliedtherapeutics.com
IPO
Date
May 14, 2019
Employees
35
Officers
Mr. Les D. Funtleyder
Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director
Dr. Riccardo Perfetti M.D., Ph.D.
Chief Medical Officer
Mr. Constantine Chinoporos
Chief Operating Officer & Chief Business Officer
Dr. Todd F. Baumgartner M.D., M.P.H.
Chief Regulatory Officer
Ms. Reena Thomas Colacot
Head of Quality
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Mr. Corwin Dale Hooks
Chief Commercial Officer
Mr. John H. Johnson
Executive Chairman